Articles On Race Oncology (ASX:RAC)

Race Oncology demonstrates positive results in melanoma therapy HITIQ extends deal with NZ Rugby Arovella set to launch in Australia Race Oncology (ASX:RAC)’s study of lead drug Zantrene in cancer immunotherapy has demonstrated positive r...

Interim results from a Race Oncology (RAC) preclinical research program show its Zantrene drug has the potential to enhance immunotherapy outcomes in melanoma Race says the research program has found that used at low concentrations, Zantr...

The Race Oncology Ltd (ASX: RAC) share price flew higher today following a positive announcement by the pharmaceutical company. At Tuesday’s market close, Race Oncology shares ended the day up 9.90% to $1.665. Let’s take a look at what...

ShareCafeEvening Report: 9 June, 2022 by Melissa Darmawan   The Australian sharemarket fell to a four week low pulled down by banks as concerns of rising interest rates and bad debts weighed on investor sentiment. Adding to the fears were n...

Benchmark and small cap index down hard Life on the indices can be hard, unless your in energy, possibly materials Pearl Gull Iron is an island, literally and figuratively   The ASX200 and its emerging companies sidekick have retreated in...

ShareCafeLunch Report: 9 June, 2022 by Melissa Darmawan   The major banks weigh on the Australian sharemarket after the Reserve Bank of Australia announced its outsized interest rate hike this week. Investors are concerned about the impact...

The Race Oncology Ltd (ASX: RAC) share price is surging today after the specialty pharmaceutical company made an announcement regarding an on-market share buyback. At the time of writing, Race Oncology shares are swapping hands at $1.96, u...

09 Jun 2022 - A snapshot of the stocks on the move featuring, Charger Metals (ASX:CHR) and Lithium Australia (ASX:LIT), Race Oncology (ASX:RAC), and Syrah Resources (ASX:SYR).

Race Oncology (RAC) has launched an on-market share buyback program to purchase up to four million RAC shares over the next year The company is aiming to take advantage of market volatility to buy the shares in periods where the price unde...

Highlights Race Oncology expands its clinical trial in EMD AML and MDS across five new sites in Europe The study supports the Pillar 3 FDA registration ambitions and builds on Zantrene’s historical safety and efficacy in AML The clini...

Race Oncology (RAC) is set to expand its BISECT cancer trial for its Zantrene product to include five additional trial sites in Spain and Italy With the extra trial sites, Race has signed a new clinical support agreement with Parexel Inter...

Race Oncology expands its Phase 1b/2a clinical trial of Zantrene to Europe Nova Eye roll out iTrack Advance in select markets in Europe and the Asia Pacific Microba’s autoimmune disease program has officially commenced Race Oncology to ex...

Cancer treatment company Race Oncology (RAC) comes out of a trading halt to announce the completion of the first phase of its Zantrene combination study The study, conducted in Israel, dosed six patients with relapsed acute myeloid leukaem...

Highlights Race Oncology has received encouraging results from the first-stage trial of Zantrene in relapsed or refractory Acute Myeloid Leukaemia. The very heavily pre-treated AML patient population has shown encouraging clinical resp...

Race Oncology completed dosing stage of Phase, eyes Phase 2 trial Immutep presents trials data at ASCO 2022 meeting Clarity Pharma presents at the Jefferies Biotech Summit Race Oncology (ASX:RAC) has completed the dose escalation stage of...

Both ASX Small Cap and benchmark index are down about 0.5% A bleak forecast from Covid-stricken China hits resources stocks Appen in trading halt after jumping 30%     Local markets took a turn for the worse on Thursday after Chinese Prem...

The Race Oncology Ltd (ASX: RAC) share price edged higher before being frozen today. This comes after the pharmaceutical company requested its shares be placed in a trading halt. At the time of writing, Race Oncology shares are on ice at $...

Highlights: Race Oncology is riding high with governance approval for human trial of its new therapy Zantrene®. The cancer drug will be studied in patients with extramedullary Acute Myeloid Leukaemia (AML) or high-risk Myelodysplastic...

Race Oncology (RAC) receives governance approval for a clinical trial of Zantrene in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) Together with ethics approval and completion of site training due to start...

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Race Oncology (ASX:RAC) has received human ethics approval for its open-label clinical trial of Zantrene in patients with extramedullary Acute Myeloid Leukaemia or high-risk Myelodysplastic Syndrome.

The ASX200 has taken a 0.5% hit on Wednesday, with the tech sector giving back all the previous session’s gains after Wall Street fell and the tech-laden Nasdaq Composite lost 2.3% overnight. The overnight session was dominated by comments...

Race Oncology (RAC) receives human ethics approval for its clinical trial of Zantrene in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) Before patients can be enrolled and treated at the lead site, Race must...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Race Oncology (ASX:RAC) has shared the interim results from the extramedullary acute myeloid leukaemia preclinical program led by cancer researcher, Associate Professor Nikki Verrills.

Race Oncology (RAC) is rapidly advancing its cancer drug as a possible new treatment option for patients with extramedullary acute myeloid leukaemia The news comes after a preclinical program, which found low doses of Zantrene, in combinat...

Race Oncology (ASX:RAC) has shared the final results from the clear cell renal cell carcinoma preclinical program led by eminent cancer researcher, Associate Professor Nikki Verrills of The University of Newcastle and Hunter Medical...

Shares in Race Oncology Ltd (ASX: RAC) are soaring and trading 5% in the green at $2.77 apiece. At one point investors had bid up the share price to $2.99 before it levelled off. The company’s lead drug compound, Zantrene, is back in the...

Race Oncology (RAC) has revealed its Zantrene product can kill a range of kidney cancer cells both on its own and in combination with existing cancer treatments The company recently completed a preclinical program testing the drug on the m...

“Advanced kidney cancer has a large unmet need for improved treatment options and Zantrene in combination with existing treatments may offer new hope for patients with this devastating disease," says chief scientific officer Dr Daniel Tille...

Shares in Race Oncology Ltd (ASX: RAC) soaring today to finish trading 14% higher in the green. The Race Oncology share price flamed higher despite no market-sensitive information from the company’s camp, nor was there any major upsets in...

Today wasn’t a great day for most ASX shares. The All Ordinaries Index (ASX: XAO) ended up losing 0.93% over this Tuesday’s trading session. But that loss was eclipsed by the Race Oncology Ltd (ASX: RAC) share price. Race shares ended up f...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Race Oncology (ASX: RAC) has announced the publication of a peer-reviewed preclinical study that has identified additional drug combinations showing synergy with its cancer-fighting drug Zantrene when tested in acute myeloid leukaemia (AML)...

Race Oncology (RAC) announces its lead Zantrene drug has been found to show synergy with several other drug combinations when tested in Acute Myeloid Leukaemia cells Researchers from the MD Anderson Cancer Center in Texas found a number of...

Inoviq (ASX:IIQ) has been granted a Brazilian patent covering the use of BARD1 isoforms in lung and colorectal cancer. Specifically, the patent covers a method for detecting the presence of the specific BARD1 isoforms, and a method for disc...

“This work provides further preclinical data to support our upcoming Phase 1b/2 extramedullary AML trial in Australian and Europe, where patients will be treated with Zantrene in combination with decitabine or cytarabine,” CHM chief scienti...

They say if you can’t measure it, you can’t manage it – and that holds particularly true when it comes to sustainability. While all the talk has been on achieving net zero by 2050, little has been done to address the lack of mandatory repor...

Disclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our in...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Race Oncology (ASX: RAC) executive director and entrepreneur Dr Daniel Tillett has joined smart energy software as a service company Simble Solutions (ASX: SIS) to help drive commercialisation of its CarbonView and SimbleSense ESG (environm...

The ASX200 has vacillated all of Monday in a whiny, unattractive way for a major global index. Like a Kardashian (name one) unable to get out of bed, the heavyweight financial names and the major miners are just dragging everyone lower, dow...

Christina Manfre, a partner at PKF Sydney, will provide leadership to Race Oncology’s financial analysis, reporting and strategic financial needs.

Race Oncology (RAC) reports $1.8 million in cash outflows for the quarter, an increase from the $931,000 in outflows recorded in the previous quarter The company spent $890,000 during the period for research and development RAC’s focus is...

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart protection has been made Oversubscribed share purchase plan has raised $29.7 million The Race Oncology Ltd (ASX: RAC) share price is...

Key points Firebrick Pharma will debut on the ASX at 12:30pm AEDT today The company is developing a nasal spray to help treat the common cold. It’s product will also undergo a COVID-19 trial Shares in the company were offered for 20 cents...

“The increased refund for FY21 is representative of the enhanced investment we made into R&D as we expanded our Zantrene clinical and supporting programs," says MD.